Trial Profile
A Phase 2, Investigator-Initiated, Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Relamorelin (Primary)
- Indications Anorexia nervosa; Gastrointestinal disorders
- Focus Proof of concept; Therapeutic Use
- Sponsors Rhythm; Rhythm Pharmaceuticals
- 02 Jan 2018 Primary endpoint of effect of RM-131 on body weight has not been met, according to results published in the Journal of Clinical Psychiatry.
- 02 Jan 2018 Results published in the Journal of Clinical Psychiatry
- 04 Apr 2016 According to a Motus media release, the results of this trial were presented at the ENDO2016 conference.